MannKind Corporation Reports 2013 Second Quarter Financial Results Business Wire VALENCIA, Calif. -- August 9, 2013 MannKind Corporation (Nasdaq: MNKD) today reported financial results for the second quarter ended June 30, 2013. For the second quarter of 2013, total operating expenses were $41.6 million, compared to $44.1 million for the second quarter of 2012, a decrease of $2.5 million. Research and development (R&D) expenses were $27.1 million for the second quarter of 2013 compared to $26.6 million for the same quarter in 2012, an increase of $0.5 million primarily due to an increase in non-cash stock compensation expense partially offset by a decrease in clinical trial related expenses. General and administrative (G&A) expenses decreased by $2.9 million to $14.5 million for the second quarter of 2013 compared to $17.4 million in the second quarter of 2012. This 17% decrease in G&A expense was primarily due to non-cash expenses of a $7.7 million litigation settlement accrual recorded in the second quarter of 2012 partly offset by increased stock compensation expense in the second quarter of 2013. Operating expenses totaled $78.0 million for the first six months of 2013 and for the same period in 2012. Total R&D expenses for the six months ended June 30, 2013 increased $2.7 million, or 5%, compared to the same period in 2012, primarily due to an increase in non-cash stock compensation expense partially offset by a decrease in clinical trial related expense in the first half of 2013. G&A expenses decreased by $2.6 million, or 10%, to $24.6 million for the first half of 2013 as compared to $27.2 million in the same period in 2012. The decrease was due to the non-recurrence of a $7.7 million litigation settlement accrual recorded in the second quarter of 2012 partially offset by increased stock compensation expense in the first half of 2013. The net loss applicable to common stockholders for the second quarter of 2013 was $46.1 million, or $0.16 per share based on 284.0 million weighted average shares outstanding, compared with a net loss applicable to common stockholders of $36.6 million, or $0.23 per share based on 159.9 million weighted average shares outstanding for the second quarter of 2012. The number of common shares outstanding at June 30, 2013 was 300,869,683. Cash and cash equivalents were $28.5 million at June 30, 2013 and $61.8 million at December 31, 2012 with $125.4 million remaining available for future borrowings under the loan agreement with The Mann Group through September 30, 2013. Conference Call As previously indicated, MannKind will hold a conference call to discuss the financial results when the results of Studies 171 and 175 are available. The analysis of these studies is expected to be completed shortly. About MannKind Corporation MannKind Corporation (Nasdaq: MNKD) focuses on the discovery, development and commercialization of therapeutic products for patients with diseases such as diabetes. Its lead product candidate, AFREZZA®, is in late stage clinical investigation for the treatment of adults with type 1 or type 2 diabetes for the control of hyperglycemia. MannKind maintains a website at http://www.mannkindcorp.com to which MannKind regularly posts copies of its press releases as well as additional information about MannKind. Interested persons can subscribe on the MannKind website to e-mail alerts that are sent automatically when MannKind issues press releases, files its reports with the Securities and Exchange Commission or posts certain other information to the website. Forward-Looking Statements This press release contains forward-looking statements, including statements related to the reporting of top-line results, that involve risks and uncertainties. Words such as "believes", "anticipates", "plans", "expects", "intend", "will", "goal", "potential" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon the Company's current expectations. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, difficulties or delays in obtaining regulatory feedback or completing and analyzing the results of clinical studies, MannKind’s ability to manage its existing cash resources or raise additional cash resources, stock price volatility and other risks detailed in MannKind's filings with the Securities and Exchange Commission, including the Annual Report on Form 10-K for the year ended December 31, 2012 and periodic reports on Form 10-Q and Form 8-K. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement, and MannKind undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this press release. MannKind Corporation (A Development Stage Company) Condensed Consolidated Statements of Operations (Unaudited) (In thousands, except per share amounts) Cumulative period from February Three months ended Six months ended 14, 1991 June 30, June 30, (date of inception) to June 30, 2013 2012 2013 2012 2013 Revenue $ — $ — $ — $ — $ 3,166 Operating expenses: Research and 27,052 26,638 53,450 50,794 1,521,023 development General and 14,533 17,416 24,572 27,193 450,276 administrative In-process research and — — — — 19,726 development costs Goodwill — — — — 151,428 impairment Total operating 41,585 44,054 78,022 77,987 2,142,453 expenses Loss from (41,585 ) (44,054 ) (78,022 ) (77,987 ) (2,139,287 ) operations Other income 15 13,347 38 14,729 (2,229 ) (expense) Interest expense on note payable (1,689 ) (3,028 ) (3,378 ) (6,076 ) (42,203 ) to related party Interest expense on senior (2,866 ) (2,844 ) (5,729 ) (5,419 ) (45,662 ) convertible notes Interest 1 1 2 2 36,998 income Loss before benefit for (46,124 ) (36,578 ) (87,089 ) (74,751 ) (2,192,383 ) income taxes Income tax — — — — 382 benefit Net loss (46,124 ) (36,578 ) (87,089 ) (74,751 ) (2,192,001 ) Deemed dividend related to beneficial conversion — — — — (22,260 ) feature of convertible preferred stock Accretion on redeemable — — — — (952 ) preferred stock Net loss applicable to $ (46,124 ) $ (36,578 ) $ (87,089 ) $ (74,751 ) $ (2,215,213 ) common stockholders Net loss per share applicable to common $ (0.16 ) $ (0.23 ) $ (0.31 ) $ (0.49 ) stockholders — basic and diluted Shares used to compute basic and diluted net loss per 284,044 159,859 282,062 151,506 share applicable to common stockholders MannKind Corporation (A Development Stage Company) Condensed Consolidated Balance Sheet (Unaudited) (in thousands) June 30, 2013 December 31, 2012 Assets Current assets: Cash and cash $ 28,529 $ 61,840 equivalents Prepaid expenses and 3,633 4,970 other current assets Total current assets 32,162 66,810 Property and equipment — 179,567 183,961 net Other assets 700 543 Total $ 212,429 $ 251,314 Liabilities and Stockholders’ Deficit Current liabilities $ 266,782 $ 144,775 Senior convertible notes 98,004 97,583 Note payable to related — 119,635 party Stockholders’ deficit (152,357 ) (110,679 ) Total $ 212,429 $ 251,314 Contact: MannKind Corporation Matthew J. Pfeffer Chief Financial Officer 661-775-5300 email@example.com
MannKind Corporation Reports 2013 Second Quarter Financial Results
Press spacebar to pause and continue. Press esc to stop.